27. Walker Z, Grace J, Overshot R, Satarasinghe S, Swan A, Katona CL et al. Olanzapine in dementia with Lewy bodies: a clinical study. Int J Geriatr Psychiatry 1999; 14 (6): 459-66.
28. Street JS, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry 2000; 57 (10): 968-976.
29. De Deyn PP, Carrasco MM, Deberdt W, Jeandel C, Hay DP, Feldman PD et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer’s disease. Int J Geriatr Psychiatry 2004; 19 (2): 115-126.
30. Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology 1997; 48 (5 Suppl 6): S10-S16.
31. Madhusoodanan S, Suresh P, Brenner R, Pillai R. Experience with the atypical antipsychotics-risperidone and olanzapine in the elderly. Ann Clin Psychiatry 1999; 11 (3): 113-118.
32. Ellingrod VL, Schultz SK, Ekstam-Smith K, Kutscher E, Turvey C, Arndt S. Comparison of risperidone with olanzapine in elderly patients with dementia and psychosis. Pharmacotherapy 2002; 22 (1): 1-5.
33. Fontaine CS, Hynan LS, Koch K, Martin-Cook K, Svetlik D, Weiner MF. A double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities. J Clin Psychiatry 2003; 64 (6): 726-730.
34. Martin H, Slyk MP, Deymann S, Cornacchione MJ. Safety profile assessment of risperidone and olanzapine in long-term care patients with dementia. J Am Med Dir Assoc 2003; 4 (4): 183-188.
35. McManus DQ, Arvanitis LA, Kowal-cyk BB. Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. J Clin Psychiatry 1999; 60 (5): 292-8.
36. Salzman C. Treatment of the agitation of late-life psychosis and Alzheimer’s disease. Eur Psychiatry 2001; 16 Suppl 1: 25s-28s.
37. Targum SD, Abott JL. Efficacy of quetiapine in Parkinson’s patients with psychosis. J Clin Psychopharmacol 2000; 20 (1): 54-60.
38. Wolters EC, Berendse HW. Management of psychosis in Parkinson’s disease. Curr Opin Neurol 2001; 14 (4): 499-504.
39. Scharre DW, Chang SI. Cognitive and behavioral effects of quetiapine in Alzheimer disease patients. Alzheimer Dis Assoc Disord 2002; 16 (2): 128-130.
40. Takahashi H, Yoshida K, Sugita T, Higuchi H, Shimizu T. Quetiapine treatment of psychotic symptoms and aggressive behavior in patients with dementia with Lewy bodies: a case series. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27 (3): 549-553.
41. Fernández HH, Trieschmann ME, Burke MA, Friedman JH. Quetiapine for psychosis in Parkinson’s disease versus dementia with Lewy bodies. J Clin Psychiatry 2002; 63 (6): 513-515.
42. Wilner KD, Tensfeldt TG, Baris B, Smolarek TA, Turncliff RZ, Colburn WA et al. Single-and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. Br J Clin Pharmacol 2000; 49 Suppl 1: 15S-20S.